Harvard Bioscience (HBIO) Equity Income (2023 - 2024)
Harvard Bioscience (HBIO) reported Equity Income of -$281000.0 for Q2 2024, up 82.23% year-over-year from -$154203.7 in Q3 2023, and up 78.58% quarter-over-quarter from -$1.3 million in Q1 2024.
Harvard Bioscience (HBIO) Equity Income (2023 - 2024) Analysis & Trends
Harvard Bioscience (HBIO) has 2 years of Equity Income data on file, last reported at -$281000.0 in Q2 2024.
- Equity Income for Q2 2024 came in at -$281000.0, up 82.23% year-over-year; the trailing twelve-month figure through Mar 2025 was -$281000.0 (up 85.55% YoY), and the FY2024 annual result was -$1.6 million, down 152.06% from the prior year.
- Equity Income advanced to -$281000.0 in Q2 2024 per HBIO's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Equity Income peaked at $1.2 million in Q3 2023 and troughed at -$1.6 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | - |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | - |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | - |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 1.72 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 3.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | - |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | - |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | - |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | - |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -281,000.00 |
| Mar 31, 2024 | -1.31 Mn |
| Dec 31, 2023 | -259,000.00 |
| Sep 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | -1.58 Mn |